Comparison of the effect of reversible and irreversible MAO inhibitors on renal nerve activity in the anesthetized rat

  • G. Lavian
  • J. P. M. Finberg
  • M. B. H. Youdim
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)


Cardiovascular effects of the irreversible MAO-A inhibitor clorgyline and reversible MAO-inhibitors, moclobemide and brofaromine, were compared in the anesthetized rat. Electrical activity of the sympathetic renal nerve was monitored as an index of central sympathetic output. A long lasting decrease in the recorded parameters: blood pressure (BP), renal nerve activity (RNA) and heart rate (HR) was produced by acute administration of clorgyline (2 mg/Kg, IP). Acute treatment with moclobemide (10 mg/Kg, IP) or brofaromine (10 mg/Kg, IP) caused only a transient decrease in RNA. Pretreatment with the α2 antagonist yohimbine, decreased significantly the inhibitory effect of clorgyline on all three parameters. The selective α2 antagonist CH-38083 blocked the sympathoinhibitory effect of brofaromine. These results indicate an α2 adrenoceptor involvement in the central sympathoinhibitory effect of MAO inhibitors, which may be manifested as a hypotensive effect, including orthostatic hypotension, in patients treated with irreversible selective MAO inhibitors.


Monoamine Oxidase Antagonist Yohimbine Renal Nerve Activity Yohimbine Hydrochloride Sympathoinhibitory Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ashkenazi R, Finberg JPM, Youdim MBH (1983) Effect of LM5008, a selective inhibitor of 5-hydroxy-tryptamine uptake, in blood pressure and responses to sympathomimetic amines. Br J Pharmacol 79: 915–922.PubMedGoogle Scholar
  2. Brown DL, Guyenet PG (1984) Cardiovascular neurons of brain stem with projections to the spinal cord. Am J Physiol 247: R1009–1016.PubMedGoogle Scholar
  3. Coote JH, Dalton DW, Feniuk FW, Humphrey PP (1987) The central site of sympathoinhibitory action of 5-hydroxy tryptamine in the cat. Neuropharmacology 26: 147–154.PubMedCrossRefGoogle Scholar
  4. Da Prada M, Kettler R, Burkard WP, Haefely WE (1984) Moclobemide, an antidepressant with short-acting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: Tipton KF, Dosiert P, Strolin-Benedetti M (eds) Monoamine oxidase and disease. Prospect for therapy with reversible inhibitors. Academic Press, London, pp 137–154.Google Scholar
  5. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248: 400–414.PubMedGoogle Scholar
  6. Denney RM, Denney CB (1985) An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and MAO B. Pharmacol Ther 30: 227–259.PubMedCrossRefGoogle Scholar
  7. Finberg JPM, Youdim MBH (1983) Selective MAO A and B inhibitors: their mechanism of action and pharmacology. Neuropharmacology 22: 441–446.PubMedCrossRefGoogle Scholar
  8. Finberg JPM, Youdim MBH (1988) Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. J Neural Transm [Suppl] 26: 11–16.Google Scholar
  9. Fozard JR, Mir AK, Middlemiss DN (1987) Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetraline (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol 9: 328–347.PubMedCrossRefGoogle Scholar
  10. Fuentes JA, Ordaz A, Neff NH (1979) Central mediation of the antihypertensive effect of pargyline in spontaneous hypertensive rats. Eur J Pharmacol 57: 21–27.PubMedCrossRefGoogle Scholar
  11. Gasic S, Korn A, Eichler HC, Oberhummer I, Zapotoczky HG (1983) Cardiocirculatory effects of moclobemide (RO 11-1163), a new reversible, short acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients. Eur J Clin Pharmacol 25: 173–177.PubMedCrossRefGoogle Scholar
  12. Goridis C, Neff NH (1971) Monoamine oxidase in sympathetic nerves: a transmitter specific enzyme type. Br J Pharmacol 43: 814–818.PubMedGoogle Scholar
  13. Graefe K-H, Boenisch H, Trendelenburg U (1971) Time-dependent changes in neuronal net uptake of noradrenaline after pretreatment with pargyline and/or reserpine. Naunyn Schmiedebergs Arch Pharmacol 271: 1–28.PubMedCrossRefGoogle Scholar
  14. Guyenet PG, Haselton JR, Sun MK (1989) Sympathoexcitatory neurons of the rostroventral medulla and the origin of the sympathetic vasomotor tone. In: Cirielo J, Caverson MM, Polosa C (eds) Progress in brain research, vol 91. Elsevier, p 105.Google Scholar
  15. Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M (1992) Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 106: S6–S14.PubMedCrossRefGoogle Scholar
  16. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 614–627.Google Scholar
  17. Korn A, Da Prada M, Raffesberg W, Gasic S, Eichler HG (1988) The effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 11: 17–23.PubMedCrossRefGoogle Scholar
  18. Kuhn DM, Wolf WA, Lovenberg W (1980) Review of the role of central serotonergic neural system in blood pressure regulation. Hypertension 2: 243–255.PubMedGoogle Scholar
  19. Lavian G, Dibona G, Finberg JPM (1991) Inhibition of sympathetic nerve activity by administration of the tricyclic antidepressant desipramine. Eur J Pharmacol 194: 153–159.PubMedCrossRefGoogle Scholar
  20. McCall RB, Harris LT, King KA (1991) Sympatholytic action of yohimbine mediated by 5-HT1A receptors. Eur J Pharmacol 199: 263–265.PubMedCrossRefGoogle Scholar
  21. Moeller HJ, Wendt G, Waldmeier P (1991) Brofaromine — a selective, reversible and short-acting MAO-A inhibitor: Review of the pharmacological and clinical findings. Pharmacopsychiatry 24: 50–54.CrossRefGoogle Scholar
  22. Neff NH, Goridis C (1972) Neuronal monoamine oxidase: specific enzyme types and their rate of formation. In: Costa E, Sandler M (eds) Monoamine oxidase and the monoamine oxidase inhibitor drugs—new vistas. Raven Press, New York, p 307.Google Scholar
  23. Neff NH, Yang NYT (1974) Another look at the monoamine oxidase inhibitor drugs. Life Sci 14: 2061–2074.PubMedCrossRefGoogle Scholar
  24. Neff NH, Yang HYT, Fuentes JA (1974) The use of selective monoamine metabolism in brain. In: Usdin E (eds) Neuropharmacology of monoamines and their regulatory enzymes. Raven Press, New York, p 49 (Adv Biochem Psychopharmacol, vol 12).Google Scholar
  25. Paton DM (1973) Mechanisms of efflux of noradrenaline from adrenergic nerves in rabbit atria. Br J Pharmacol 49: 614–627.PubMedGoogle Scholar
  26. Takahashi H (1985) Cardiovascular and sympathetic response to intracarotid and intravenous injection of serotonin in rats. Arch Pharmacol 329: 222–226.CrossRefGoogle Scholar
  27. Vizi ES, Harsing LG JR, Gaal J, Kapocsi J, Bernath S, Somogyi GT (1986) CH-38083, a selective, potent antagonist of alpha-2 adrenoceptors. J Pharmacol Exp Ther 238: 701–706.PubMedGoogle Scholar
  28. Waldmeier PC, Staecklin K (1989) The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur J Pharmacol 169: 197–204.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • G. Lavian
    • 1
  • J. P. M. Finberg
    • 1
  • M. B. H. Youdim
    • 1
  1. 1.Department of PharmacologyBruce Rappaport Faculty of Medicine, TechnionHaifaIsrael

Personalised recommendations